weight loss

Adam Mendelsohn, CEO of Vivani Medical, holds the miniature semaglutide (GLP-1) implant designed for once- or twice-yearly administration.
Jul 8, 2026

Novo Nordisk to evaluate semaglutide weight loss implant

Novo Nordisk will evaluate Vivani Medical's semaglutide implant for chronic weight management under a new development agreement.

Dietary supplements
Apr 2, 2026

Noom acquires compounding pharmacy to expand health care services

Noom's acquisition of Tailor Made Compounding aims to help the company expand beyond weight loss into preventive health and healthy aging, adding personalized therapies and pharmacy capabilities.

Novo Nordisk is the sole patent holder of semaglutide – the active ingredient in popular diabetes shot Ozempic and as well as blockbuster weight loss drug Wegovy. The company has said it is not supplied to outside entities.
Feb 26, 2025

Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)

An industry group filed the lawsuit after the health regulator removed semaglutide from its shortage list and told manufacturers they need to stop producing unbranded versions within the next 60 to 90 days.